191 related articles for article (PubMed ID: 25870069)
1. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
2. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
3. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
[No Abstract] [Full Text] [Related]
8. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
9. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
10. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
Edstein MD; Kocisko DA; Brewer TG; Walsh DS; Eamsila C; Charles BG
Br J Clin Pharmacol; 2001 Dec; 52(6):663-70. PubMed ID: 11736877
[TBL] [Abstract][Full Text] [Related]
13. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
Thakkar N; Green JA; Koh GCKW; Duparc S; Tenero D; Goyal N
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201820
[TBL] [Abstract][Full Text] [Related]
18. Tafenoquine: First Global Approval.
Frampton JE
Drugs; 2018 Sep; 78(14):1517-1523. PubMed ID: 30229442
[TBL] [Abstract][Full Text] [Related]
19. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
20. Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Srinivasan S; Roy D; Chavas TEJ; Vlaskin V; Ho DK; Pottenger A; LeGuyader CLM; Maktabi M; Strauch P; Jackson C; Flaherty SM; Lin H; Zhang J; Pybus B; Li Q; Huber HE; Burke PA; Wesche D; Rochford R; Stayton PS
J Control Release; 2021 Mar; 331():213-227. PubMed ID: 33378692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
